SavedAdd your journal

Journals / Journal of Health Sciences and Medicine / 2026 / Volume: 9 Issue: 6

The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS)

Şerife Ezgi Doğan(Sincan Eğitim ve Araştırma Hastanesi)0000-0003-0526-7647
Özge Yücel Çelik(YÜKSEK İHTİSAS ÜNİVERSİTESİ)0000-0002-7746-1943
Pages
—
Publication Date
2026-10-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Since BMI adjustment eliminates metabolic differences between classical and non-classical phenotypes, therapeutic interventions may focus on weight loss and obesity treatment for all phenotypes of PMOS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: The purpose of this study is to identify relationship between new metabolic indices -namely Triglyceride Glucose Index (TyG), lipid accumulation product (LAP), and Visceral Adiposity Index (VAI) are investigated-and classical and nonclassical polyendocrine metabolic ovarian syndrome (PMOS) phenotypes.
📊
Key Findings & Data:Methods: Data were evaluated retrospectively which collected from 103 patients with PMOS (59 classical phenotypes, 44 nonclassical phenotypes).
💡
Conclusion & Impact:Conclusion: Since BMI adjustment eliminates metabolic differences between classical and non-classical phenotypes, therapeutic interventions may focus on weight loss and obesity treatment for all phenotypes of PMOS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Polyendocrine metabolic ovarian syndrome · Triglyceride Glucose Index · lipid accumulation product

Abstract

Aims: The purpose of this study is to identify relationship between new metabolic indices -namely Triglyceride Glucose Index (TyG), lipid accumulation product (LAP), and Visceral Adiposity Index (VAI) are investigated-and classical and nonclassical polyendocrine metabolic ovarian syndrome (PMOS) phenotypes. Methods: Data were evaluated retrospectively which collected from 103 patients with PMOS (59 classical phenotypes, 44 nonclassical phenotypes). Results: Classical phenotypes group has higher body-mass index (BMI), weight, waist circumference, waist height ratio, LH levels, TyG, LAP and VAI levels than non-classical phenotypes. In according to lipid profiles, classical PMOS group has more atherogenic trend. The difference between groups in TyG, LAP and VAI is eliminated after adjustment for BMI. Conclusion: Since BMI adjustment eliminates metabolic differences between classical and non-classical phenotypes, therapeutic interventions may focus on weight loss and obesity treatment for all phenotypes of PMOS.

🔖

Cite This Article

Doğan, Ş. E., Çelik, Ö. Y. (2026). The impact of body-mass index on new metabolic indices between classical and nonclassical phenotypes of polyendocrine metabolic ovarian syndrome (PMOS). Journal of Health Sciences and Medicine, Volume: 9 Issue: 6. https://ajindex.com/articles/1668068

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (29)

  1. Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026. doi:10.1016/S0140-6736(26)00717-8
  2. Helvaci N, Yildiz BO. The impact of ageing and menopause in women with polycystic ovary syndrome. Clin Endocrinol. 2022;97(3):371-382. doi:10.1111/CEN.14558
  3. Morshed S, Banu H, Hossan S, Mahrukh H, Hasanat MA. Association of adiposity indices with insulin resistance among women with polycystic ovary syndrome. Clin Exp Reprod Med. 2025;52(4):342-347. doi:10.5653/cerm.2024.07388
  4. Parsaei M, Karimi E, Barkhordarioon A, Yousefi M, Tarafdari A. Lipid accumulation product and Visceral Adiposity Index in polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Lipids Health Disease. 2025;24(1):311. doi:10.1186/S12944-025-02719-Y
  5. Seyedi SA, Nabipoorashrafi SA, Amin Afshari S, et al. Lipid Accumulation Product Index as a marker of metabolic syndrome in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrinol Diabet Metabol. 2025;8(5):e70078. doi:10.1002/edm2.70078
  6. Fauser BCJM, Tarlatzis, Fauser, et al. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19(1):41-47. doi:10.1093/HUMREP/DEH098
  7. Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist–Hip Ratio. Eur J Clin Nutrit. 2010;64:2-5. doi:10.1038/ejcn.2009.139
  8. Yang HS, Kim SN, Lee S, Hur M. The validation of a novel, sex-specific LDL-cholesterol equation and the Friedewald, Sampson-NIH, and extended-Martin-Hopkins equations against direct measurement in Korean adults. Metabolites. 2025;15(1):18. doi:10.3390/metabo15010018
  9. Bhattacharya K, Sengupta P, Dutta S, Chaudhuri P, Das Mukhopadhyay L, Syamal AK. Waist-to-height ratio and BMI as predictive markers for insulin resistance in women with PCOS in Kolkata, India. Endocrine. 2021;72(1):86-95. doi:10.1007/S12020-020-02555-3
  10. Savran Üçok B, Dikici Aktaş T, Özalp E, et al. Comparative analysis of hormonal and metabolic indices in phenotypic subgroups of polycystic ovary syndrome. J Turk German Gynecol Assoc. 2026;27(1):29-35. doi:10.4274/jtgga.galenos.2026.2025-9-22
  11. Cavnar Helvacı B, Hepşen S, Candemir B, Çakal E. Evaluating the triglyceride glucose index as a novel method for assessing insulin resistance in Turkish women with polycystic ovary syndrome. J Med Palliat Care. 2025;6(1):33-38. doi:10.47582/jompac.1601449
  12. Nowak J, Jabczyk M, Borszcz J, Jagielski P, Zubelewicz-Szkodzińska B. Clinical utility of anthropometric parameters in identifying glucose dysregulation in women with polycystic ovary syndrome. Front Endocrinol. 2026;16:1756679. doi:10.3389/fendo.2025.1756679
  13. Bilginer MC, Tüfekçi D, Emür Günay Y, et al. Evaluation of insulin resistance measurement methods in patients with polycystic ovary syndrome. Turk J Diab Obes. 2022;6(1):24-31. doi:10.25048/tudod.1041387
  14. Dadachanji R, Patil A, Joshi B, Mukherjee S. Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women. PLoS One. 2021;16(2):e0246862. doi:10.1371/journal.pone.0246862
  15. Wen X, Wang L, Bai E. Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2024;15:1370578. doi:10.3389/fendo.2024.1370578
  16. Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E, Dilbaz S. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. J Obstet Gynaecol Res. 2016;42(7):837-843. doi:10.1111/jog.12985
  17. Pikee S, Shivani S, Jayshree B. Endocrine and metabolic profile of different phenotypes of polycystic ovarian syndrome. J Obstet Gynaecol India. 2016;66(suppl 1):560-566. doi:10.1007/s13224-016-0898-7
  18. Rashidi H, Ramezani Tehrani F, Bahri Khomami M, Rostami Dovom M, Noroozzadeh M, Azizi F. The prevalence of various phenotypes of polycystic ovary syndrome: a community-based study in southwest of Iran. Iranian J Endocrinol Metabol. 2014;16(2):119-126.
  19. Sobti S, Dewan R, Ranga S. Metabolic syndrome and insulin resistance in PCOS phenotypes. Int J Reprod Contracept Obstet Gynecol. 2017;6(11):5067-5073. doi:10.18203/2320-1770.ijrcog20175027
  20. Singh N, Hooja N, Batar A, Jaiswal A, Bairwa P. A study of central fat accumulation indices amongst different polycystic ovary syndrome phenotypes. Int J Sci Res Arch. 2022;6(1):284-287. doi:10.30574/ijsra.2022.6.1.0132
  21. Pluta D, Staśczak A, Stokowy T, Migacz M, Kochman K, Holecki M. Visceral adiposity index in relation to Rotterdam phenotypes of polycystic ovary syndrome. Biomedicines. 2025;13(8):1997. doi:10.3390/biomedicines13081997
  22. Soares Jr JM, Hayashida SAY, Marcondes JAM, et al. Influence of phenotypes on the metabolic syndrome of women with polycystic ovary syndrome over a six-year follow-up in Brazil. Biomedicines. 2023;11(12):3262. doi:10.3390/biomedicines11123262
  23. Akkus C, Oner O, Kilic AO, Duran C. Visceral adiposity index (VAI) levels and metabolic risk across phenotypes of polycystic ovary syndrome (PCOS). Medicina (Kaunas). 2025;61(9):1673. doi:10.3390/medicina61091673
  24. Hosseinpanah F, Barzin M, Keihani S, Ramezani Tehrani F, Azizi F. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS prevalence study. Clin Endocrinol (Oxf). 2014;81(1):93-99. doi:10.1111/cen.12406
  25. Gunay YE, Kişioğlu SV, Karakullukçu S, et al. Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups. Rev Assoc Med Bras (1992). 2023;69(7):e20230174. doi:10.1590/1806-9282.20230174
  26. Önal M, Çalı Öztürk H. Anti-Müllerian hormone and HOMA-IR in different phenotypes of polycystic ovary syndrome on insulin resistance. Anatolian Curr Med J. 2023;5(4):376-382. doi:10.38053/acmj.1323489
  27. Javidan A, Azarboo A, Jalali S, et al. The association between Triglyceride-Glucose Index and polycystic ovary syndrome: a systematic review and meta-analysis across different populations. J Ovarian Res. 2025;18(1):163. doi:10.1186/s13048-025-01717-z
  28. Radic L, Ognjanovic S, Popovic B, et al. The Triglyceride-Glucose (TyG) Index and its relation to metabolic indices in women with PCOS: a phenotype-based analysis. Endocr Abstr. 2025;110:P1039. doi:10.1530/endoabs.110.P1039
  29. Božić-Antić I, Ilić D, Bjekić-Macut J, et al. Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome. Eur J Endocrinol. 2016;175(6):551-560. doi:10.1530/EJE-16-0775